Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial
Publication date: Available online 21 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Inge B Halberg, Karsten Lyby, Karsten Wassermann, Tim Heise, Eric Zijlstra, Leona Plum-MörschelSummaryBackgroundOral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes.MethodsThis was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes ...
Source: The Lancet Diabetes and Endocrinology - January 22, 2019 Category: Endocrinology Source Type: research

Oral insulin: time to rewrite the textbooks
Publication date: Available online 21 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Chantal Mathieu (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - January 22, 2019 Category: Endocrinology Source Type: research

Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study
This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extr...
Source: The Lancet Diabetes and Endocrinology - January 17, 2019 Category: Endocrinology Source Type: research

Careful investigation of a rare disease: insights into multiple endocrine neoplasia type 2B
Publication date: Available online 16 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Maya B Lodish (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - January 17, 2019 Category: Endocrinology Source Type: research

Low-carbohydrate diets in type 2 diabetes
Publication date: Available online 15 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Jeannie Tay, Martin I de Bock, Elizabeth J Mayer-Davis (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - January 16, 2019 Category: Endocrinology Source Type: research

Diagnosing the Legacy: The Discovery, Research, and Treatment of Type 2 Diabetes in Indigenous Youth, Larry Krotz. University of Manitoba Press (2018), 192, CAN$24·95, ISBN: 978-0887558238
Publication date: Available online 11 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ellen L Toth (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - January 12, 2019 Category: Endocrinology Source Type: research

Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
Publication date: Available online 9 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Michael P Whyte, Thomas O Carpenter, Gary S Gottesman, Meng Mao, Alison Skrinar, Javier San Martin, Erik A ImelSummaryBackgroundChildren with X-linked hypophosphataemia have high concentrations of circulating phosphatonin fibroblast growth factor 23 (FGF23), which causes renal phosphate wasting and hypophosphataemia, rickets, skeletal deformities, and growth impairment. Burosumab, a human monoclonal antibody against FGF23, improves phosphate homoeostasis and rickets in children aged 5–12 years with X-linked hypo...
Source: The Lancet Diabetes and Endocrinology - January 10, 2019 Category: Endocrinology Source Type: research

Hope for patients with X-linked hypophosphataemia?
Publication date: Available online 9 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): John M Pettifor (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - January 10, 2019 Category: Endocrinology Source Type: research

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
Publication date: Available online 8 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Josef Coresh, Hiddo J L Heerspink, Yingying Sang, Kunihiro Matsushita, Johan Arnlov, Brad C Astor, Corri Black, Nigel J Brunskill, Juan-Jesus Carrero, Harold I Feldman, Caroline S Fox, Lesley A Inker, Areef Ishani, Sadayoshi Ito, Simerjot Jassal, Tsuneo Konta, Kevan Polkinghorne, Solfrid Romundstad, Marit D Solbu, Nikita StempniewiczSummaryBackgroundChange in albuminuria as a surrogate endpoint for progression of chronic kidney disease is strongly supported by biological plausibility, but empirical evidence to support...
Source: The Lancet Diabetes and Endocrinology - January 9, 2019 Category: Endocrinology Source Type: research

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
Publication date: Available online 8 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Hiddo J L Heerspink, Tom Greene, Hocine Tighiouart, Ron T Gansevoort, Josef Coresh, Andrew L Simon, Tak Mao Chan, Fan Fan Hou, Julia B Lewis, Francesco Locatelli, Manuel Praga, Francesco Paolo Schena, Andrew S Levey, Lesley A Inker, Angel Sevillano, Anne-Lise Kamper, Arjan D. van Zuilen, Barry M. Brenner, Bart Maes, Benno U. IhleSummaryBackgroundChange in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to support its validity is l...
Source: The Lancet Diabetes and Endocrinology - January 9, 2019 Category: Endocrinology Source Type: research

Working towards novel albuminuria endpoints in chronic kidney disease
Publication date: Available online 8 January 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Beatriz Fernandez-Fernandez, Maria Dolores Sanchez-Niño, Alberto Ortiz (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - January 9, 2019 Category: Endocrinology Source Type: research

Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes
Publication date: Available online 20 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Yiqiao Xin, Andrew Davies, Louise McCombie, Andrew Briggs, C-Martina Messow, Eleanor Grieve, Wilma S Leslie, Roy Taylor, Michael E J Lean (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 21, 2018 Category: Endocrinology Source Type: research

New pharmacological strategies for protecting kidney function in type 2 diabetes
Publication date: Available online 19 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marcel H A Muskiet, David C Wheeler, Hiddo J L HeerspinkSummaryType 2 diabetes is the leading cause of impaired kidney function, albuminuria, and renal replacement therapy globally, thus placing a large burden on health-care systems. Current treatment strategies rely on intensive glucose lowering, and strict blood pressure control targeting blockade of the renin–angiotensin–aldosterone system. Such approaches might slow decline in kidney function, but many patients progress to end-stage kidney failure de...
Source: The Lancet Diabetes and Endocrinology - December 20, 2018 Category: Endocrinology Source Type: research

Novel subgroups of patients with adult-onset diabetes in Chinese and US populations
Publication date: January 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 1Author(s): Xiantong Zou, Xianghai Zhou, Zhanxing Zhu, Linong Ji (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 20, 2018 Category: Endocrinology Source Type: research

Liothyronine cost and prescriptions in England
Publication date: January 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 1Author(s): Peter N Taylor, Salman Razvi, Ilaria Muller, John Wass, Colin M Dayan, Krishna Chatterjee, Kristien Boelaert (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 20, 2018 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2019; 7: 25–33
Publication date: January 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 1Author(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 20, 2018 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2019; 7: 34–43
Publication date: January 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 1Author(s): (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 20, 2018 Category: Endocrinology Source Type: research

Research in brief
Publication date: January 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 1Author(s): Kate V McIntosh (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 20, 2018 Category: Endocrinology Source Type: research

Evidence of hypothyroidism in a portrait by Lorenzo Lotto
Publication date: January 2019Source: The Lancet Diabetes & Endocrinology, Volume 7, Issue 1Author(s): Víctor Asensi, Donatella Lippi, Antonio Perciaccante, Philippe Charlier, Otto Appenzeller, Raffaella Bianucci (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 20, 2018 Category: Endocrinology Source Type: research

Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial
This study and extension phase are registered with ClinicalTrials.gov, number NCT01205152, and EudraCT, number 2009-009369-32.Findings11 participants were recruited between Oct 6, 2008, and Dec 4, 2009. Ten patients completed a 6 month treatment period and entered the extension phase; nine received asfotase alfa for at least 6 years and completed the study, with four being treated for more than 7 years. Skeletal healing was sustained over 7 years of treatment; all evaluable patients had RGI-C scores of at least +2 at year 6 (n=9; median score +2·0 [range 2·0–3·0]) and year 7 (n=7; median score +2...
Source: The Lancet Diabetes and Endocrinology - December 15, 2018 Category: Endocrinology Source Type: research

Asfotase alfa treatment in perinatal and infantile hypophosphatasia: safe and sustained efficacy
Publication date: Available online 14 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Raja Padidela (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 15, 2018 Category: Endocrinology Source Type: research

Type 1 diabetes research: poised for progress
Publication date: Available online 6 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 7, 2018 Category: Endocrinology Source Type: research

Gender-affirming hormones and surgery in transgender children and adolescents
Publication date: Available online 6 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Simone Mahfouda, Julia K Moore, Aris Siafarikas, Timothy Hewitt, Uma Ganti, Ashleigh Lin, Florian Daniel ZepfSummaryThe Endocrine Society Clinical Practice Guidelines on the treatment of gender incongruent people recommend the use of gender-affirming cross-sex hormone (CSH) interventions in transgender children and adolescents who request this treatment, who have undergone psychiatric assessment, and have maintained a persistent transgender identity. The intervention can help to affirm gender identity by inducing mas...
Source: The Lancet Diabetes and Endocrinology - December 7, 2018 Category: Endocrinology Source Type: research

Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
Publication date: Available online 5 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Henrik Svanström, Peter Ueda, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn PasternakSummaryBackgroundTrial evidence shows that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduces the risk of major cardiovascular events among patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk. We aimed to assess the cardiovascular effective...
Source: The Lancet Diabetes and Endocrinology - December 6, 2018 Category: Endocrinology Source Type: research

GLP-1 receptor agonists and cardiovascular risk in routine clinical practice
Publication date: Available online 5 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Guntram Schernthaner, Marie Helene Schernthaner-Reiter (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 6, 2018 Category: Endocrinology Source Type: research

Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial
Publication date: Available online 4 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Jodie M Dodd, Jennie Louise, Andrea R Deussen, Rosalie M Grivell, Gustaaf Dekker, Andrew J McPhee, William HagueSummaryBackgroundMaternal overweight and obesity are associated with well recognised pregnancy complications. Antenatal dietary and lifestyle interventions have a modest effect on gestational weight gain without affecting pregnancy outcomes. We aimed to assess the effects on maternal and infant outcomes of antenatal metformin given in addition to dietary and lifestyle advice among overweight and obese pregn...
Source: The Lancet Diabetes and Endocrinology - December 5, 2018 Category: Endocrinology Source Type: research

Reassessing strategies to improve pregnancy outcomes in overweight and obese women
Publication date: Available online 4 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Patrick M Catalano (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - December 5, 2018 Category: Endocrinology Source Type: research

Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study
Publication date: Available online 28 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Elizabeth J Samelson, Kerry E Broe, Hanfei Xu, Laiji Yang, Steven Boyd, Emmanuel Biver, Pawel Szulc, Jonathan Adachi, Shreyasee Amin, Elizabeth Atkinson, Claudie Berger, Lauren Burt, Roland Chapurlat, Thierry Chevalley, Serge Ferrari, David Goltzman, David A Hanley, Marian T Hannan, Sundeep Khosla, Ching-Ti LiuSummaryBackgroundAlthough areal bone mineral density (aBMD) assessed by dual-energy x-ray absorptiometry (DXA) is the clinical standard for determining fracture risk, most older adults who sustain a fracture h...
Source: The Lancet Diabetes and Endocrinology - November 29, 2018 Category: Endocrinology Source Type: research

Improving fracture risk assessment in older adults
Publication date: Available online 28 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Elizabeth Shane (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - November 29, 2018 Category: Endocrinology Source Type: research

Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer
Publication date: Available online 27 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): R Michael Tuttle (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - November 28, 2018 Category: Endocrinology Source Type: research

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
Publication date: Available online 27 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Hakim-Moulay Dehbi, Ujjal Mallick, Jonathan Wadsley, Kate Newbold, Clive Harmer, Allan HackshawSummaryBackgroundTwo large randomised trials of patients with well-differentiated thyroid cancer reported in 2012 (HiLo and ESTIMABL1) found similar post-ablation success rates at 6–9 months between a low administered radioactive iodine (131I) dose (1·1 GBq) and the standard high dose (3·7 GBq). However, recurrence rates following radioactive iodine ablation have previously only been reported in obs...
Source: The Lancet Diabetes and Endocrinology - November 28, 2018 Category: Endocrinology Source Type: research

Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care
Publication date: Available online 21 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Hertzel C Gerstein (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - November 22, 2018 Category: Endocrinology Source Type: research

Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis
Publication date: Available online 21 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Sanjay Basu, John S Yudkin, Sylvia Kehlenbrink, Justine I Davies, Sarah H Wild, Kasia J Lipska, Jeremy B Sussman, David BeranSummaryBackgroundThe amount of insulin needed to effectively treat type 2 diabetes worldwide is unknown. It also remains unclear how alternative treatment algorithms would affect insulin use and disability-adjusted life-years (DALYs) averted by insulin use, given that current access to insulin (availability and affordability) in many areas is low. The aim of this study was to compare alternati...
Source: The Lancet Diabetes and Endocrinology - November 22, 2018 Category: Endocrinology Source Type: research

Research digest: genetics in cardiometabolic disease
Publication date: December 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 12Author(s): Naveed Sattar, Michael V Holmes, David Preiss (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - November 22, 2018 Category: Endocrinology Source Type: research

Obesogens: accounting for environmental factors in obesity
Publication date: December 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 12Author(s): Leonardo Trasande (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - November 22, 2018 Category: Endocrinology Source Type: research

Family matters in diabetes care
Publication date: Available online 14 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - November 14, 2018 Category: Endocrinology Source Type: research

Emerging paradigms of treating diabetic nephropathy
Publication date: Available online 6 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Yongen Chang, Hamid Moradi, Kamyar Kalantar-Zadeh (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - November 7, 2018 Category: Endocrinology Source Type: research

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial
Publication date: Available online 6 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Dick de Zeeuw, Ronny W Renfurm, George Bakris, Peter Rossing, Vlado Perkovic, Fan Fan Hou, Masaomi Nangaku, Kumar Sharma, Hiddo J L Heerspink, Alberto Garcia-Hernandez, Tobias E LarssonSummaryBackgroundMany patients with diabetic kidney disease have residual albuminuria and are at risk of disease progression. The ALBUM trial investigated the efficacy of a novel, orally active inhibitor of vascular adhesion protein-1, ASP8232, compared with placebo for reducing albuminuria in individuals with type 2 diabetes and chron...
Source: The Lancet Diabetes and Endocrinology - November 7, 2018 Category: Endocrinology Source Type: research

The perils of polyvascular disease in type 2 diabetes
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Subodh Verma, C David Mazer, Deepak L Bhatt (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute co...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research

The association between BMI and mortality: implications for obesity prevention
Publication date: Available online 30 October 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Deirdre K Tobias, Frank B Hu (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - October 31, 2018 Category: Endocrinology Source Type: research

Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK
Publication date: Available online 30 October 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Krishnan Bhaskaran, Isabel dos-Santos-Silva, David A Leon, Ian J Douglas, Liam SmeethSummaryBackgroundBMI is known to be strongly associated with all-cause mortality, but few studies have been large enough to reliably examine associations between BMI and a comprehensive range of cause-specific mortality outcomes.MethodsIn this population-based cohort study, we used UK primary care data from the Clinical Practice Research Datalink (CPRD) linked to national mortality registration data and fitted adjusted Cox regression...
Source: The Lancet Diabetes and Endocrinology - October 31, 2018 Category: Endocrinology Source Type: research

Oral health: a neglected aspect of diabetes care
Publication date: Available online 24 October 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Pirkko J Pussinen, Veikko Salomaa (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - October 25, 2018 Category: Endocrinology Source Type: research

The challenge of modulating β-cell autoimmunity in type 1 diabetes
Publication date: Available online 24 October 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Mark A Atkinson, Bart O Roep, Amanda Posgai, Daniel C S Wheeler, Mark PeakmanSummaryWith the conceptual advance about four decades ago that type 1 diabetes represents an autoimmune disease, hope arose that immune-based therapies would soon emerge to prevent and reverse the disorder. However, despite dozens of clinical trials seeking to achieve these goals, the promise remains unfulfilled, at least in a pragmatic form. With the benefit of hindsight, several important reasons are likely to account for this disappointin...
Source: The Lancet Diabetes and Endocrinology - October 25, 2018 Category: Endocrinology Source Type: research

Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial
This study is registered with the ISRCTN registry, number ISRCTN83229304.FindingsBetween Oct 1, 2008, and Oct 31, 2012, we randomly assigned 264 patients to IPT (n=133) or CPT (n=131), all of whom were included in the intention-to-treat population. At baseline, mean HbA1c was 8·1% (SD 1·7) in both groups. After 12 months, unadjusted mean HbA1c was 8·3% (SE 0·2) in the CPT group and 7·8% (0·2) in the IPT group; with adjustment for baseline HbA1c, age, sex, ethnicity, smoking status, duration of diabetes, and BMI, HbA1c was 0·6% (95% CI 0·3–0·9; p
Source: The Lancet Diabetes and Endocrinology - October 25, 2018 Category: Endocrinology Source Type: research

Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine
Publication date: Available online 24 October 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Bart O Roep, Daniel C S Wheeler, Mark PeakmanSummaryPrecision medicine has emerged as a mantra for therapeutic approaches to complex diseases. The defining concept relies on a detailed insight into disease pathogenesis and therapeutic mechanism. Although the type 1 diabetes field has gained new insights into disease endotypes and indications of efficacy for several therapies, none of these is yet licensed, partly because of immune suppressive side-effects beyond control of islet autoimmunity. New strategies designed ...
Source: The Lancet Diabetes and Endocrinology - October 25, 2018 Category: Endocrinology Source Type: research

Testosterone therapy and physical function
Publication date: November 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 11Author(s): Bradley D Anawalt, Stephanie T Page (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - October 24, 2018 Category: Endocrinology Source Type: research

Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials
Publication date: November 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 11Author(s): Shalender Bhasin, Susan S Ellenberg, Thomas W Storer, Shehzad Basaria, Marco Pahor, Alisa J Stephens-Shields, Jane A Cauley, Kristine E Ensrud, John T Farrar, David Cella, Alvin M Matsumoto, Glenn R Cunningham, Ronald S Swerdloff, Christina Wang, Cora E Lewis, Mark E Molitch, Elizabeth Barrett-Connor, Jill P Crandall, Xiaoling Hou, Peter PrestonSummaryBackgroundThe Physical Function Trial (PFT) was one of seven Testosterone Trials (TTrials), the aim of which was to assess the effect of testosterone on mobility, self...
Source: The Lancet Diabetes and Endocrinology - October 24, 2018 Category: Endocrinology Source Type: research

Research in brief
Publication date: November 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 11Author(s): Kate V McIntosh (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - October 24, 2018 Category: Endocrinology Source Type: research

Osteoporosis: a roadmap to close the treatment gap
Publication date: Available online 12 October 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - October 13, 2018 Category: Endocrinology Source Type: research